

ASX Announcement

26 August 2026

MERGER DISCUSSIONS BETWEEN GENETIC SIGNATURES AND MICROBA LIFE SCIENCES

- Genetic Signatures Limited (ASX: GSS) is in discussions with Microba Life Sciences Limited (ASX: MAP) about combining the two businesses.
- Microba's current product portfolio, which is focused on gastrointestinal (GI) diagnostics, is complementary to GSS' existing GI offering.
- A potential transaction would provide the combined group broader access to major pathology networks, a differentiated infectious-disease offering and further establish GSS' domestic and international footprint.

Genetic Signatures Limited (ASX: GSS) (GSS or the Company) is pleased to advise that following its previously announced strategic review, which included actively pursuing opportunities to scale, it is in discussions with Microba Life Sciences Limited (ASX: MAP) (Microba). The parties are assessing a potential merger to create a leading, scalable ASX-listed infectious disease diagnostics group. The combined group would bolster GSS' offering to encompass the full continuum of diagnostic testing from rapid, first-line pathogen detection to microbiome profiling.

While the structure and commercial aspects are still being considered, both the Microba and GSS Boards see benefits in bringing the two businesses together and are aligned in realising value for their shareholders. On a pro forma basis, the merged group would have FY2026 revenue of approximately A\$29 million and combined cash and term deposits of approximately A\$30 million as at 30 June 2026.

Strategic Rationale

- **A more sustainable financial and capital structure.** The combined group would benefit from a streamlined cost base and corporate structure with the potential to accelerate growth and pathway to profitability;
- **Broader global market access.** Both parties have strong partnerships with pathology networks, including GSS' laboratory and hospital customers across Australia, the UK and Europe, which give both product ranges a materially wider route to market; and
- **A differentiated infectious-disease offering.** GSS' regulatory approved infectious disease panels for rapid first-line detection combined with Microba's metagenomics profiling enables full-service microbiome testing.

Commentary

Caroline Waldron, Chair of Genetic Signatures, said: "The proposed combined group offers synergies and the opportunity to scale. As we progress discussions on the proposed transaction our focus will be on delivering value to our shareholders."

Pasquale Rombola, Chair of Microba, said: "A merger would create a leader in microbiome and infectious disease diagnostics, with broader revenue and customer bases, and a materially stronger balance sheet to meet the significant global opportunity facing the merged group. We look forward to continuing our work together with the GSS team to assess and realise that opportunity."

GSS is being advised by AE Advisors as corporate adviser and Gadens as legal adviser. Microba is being advised by Latimer Partners as corporate adviser and Thomsons as legal adviser.

The discussions are presently at a preliminary stage and remain incomplete and no firm or binding decision has been made to proceed with any merger and neither party is committed to proceeding. Any transaction will be subject to further due diligence, the parties obtaining all required regulatory approvals, including any approvals required by ASX. There is no certainty any terms of any transaction or offer will be agreed, nor as to the terms or of such transaction or offer, if agreed. Nothing in this announcement shall be construed as indicating any terms of such transaction or offer. A further announcement will be made as appropriate. This announcement does not constitute a proposal to make a takeover bid under section 631 of the Corporations Act.

– END –

Announcement authorised by Genetic Signatures' Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Caroline Waldron

Chair, Genetic Signatures Limited

Caroline.waldron@geneticsignatures.com

T: +61 (0)2 9870 7580

Maria Halasz

CEO, Genetic Signatures Limited

maria.halasz@geneticsignatures.com

T: +61 (0)2 9870 7580

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

About Microba Life Sciences

Microba Life Sciences Limited (ASX: MAP) is a precision microbiome company listed on the ASX since April 2022. Its diagnostics division provides clinical-grade gut microbiome testing to healthcare professionals in Australia, UK and Europe, supported by distribution relationships with Sonic Healthcare and SYNLAB. Its therapeutics pipeline includes the Phase 2-ready MAP 315 asset for ulcerative colitis.